Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChiCTR2000040133Phase 4Not yet recruiting
Phase 4 trial of sufentanil and esketamine (4 arms), sponsored by Tianjin Fourth Central Hospital. Primary endpoint: Efficacy evaluation. Planned start Dec 2020; status: not yet recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on ChiCTR2000040133.